Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.
China’s Simcere Pharmaceutical Group announced on 3 August that it had exclusively licensed G1 Therapeutics Inc.’s first-in-class, intravenous...